Weekly high-dose 5-fluorouracil 24-hour infusion and intermediate-dose folinic acid bolus in metastatic colorectal cancer

Oncology Research and Treatment

Volumn 19, Issue 5, 1996, Pages 410-414

  Stoffregen, C ^a   Zurborn, K H ^a   Boehme, V ^a   Schmid, A ^a   Lorenz, G ^a   Arendt, T ^a   Folsch U R ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

5 Fluorouracil; Folinic acid; Metastatic colorectal cancer

Indexed keywords

FLUOROURACIL; FOLIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG TOLERANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA;

EID: 0029811281     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218842     Document Type: Article

References (19)

1. Köhne-Wömpner CH, Schmoll HJ, Harslrlck A, Rustum YM: Chemolherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials Semin Oncol 1992:19:105-125.
2. Ardalan B, Chua L, Han E, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morell L, Freun L, Savaraj N, Livingstone A: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma, J Clin Oncol 1991;9:625-630.
3. Welt HJ, Dierlamm J, Hossfeld DK: Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma, Eur J Cancer 1994;30A:890-891.
4. Weh HJ, Wilke HJ, Dierlamm J, Klaasscn U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U, Stein-ke B, Weber W, Burkhard O, Zoller A, Pfitzner J, Subert R, Kriebel R, Hossfeld DK: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma, Ann Oncol 1994;5:233-237.
5. Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment, Cancer 1981:47:207-214.
6. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations Am Stat Assoc 1958:53:457-481.
7. Stetson PL, Shukla UA, Ensminger WD: Sensitive high-performance liquid chromatographic method for the determination of 5-fluorouracil in plasma, J Chromatogr 1985:344:385-390.
8. Graf W, Pahlman L, Bergstrom R, Glimelius B:The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer, Br J Cancer 1994:70:559-563.
9. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomiz, ed comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study, J Clin Oncol 1989:7:425-432.
10. Erlichman C, Fine S, Elhakim T: Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol, Cancer Treat Rep 1986;70:903-904.
11. Remick SC, Grem JL, Fischer PH, Tutsch KD, Alberti DB, Nieting LM, Tombes MB, Bruggink J, Willson JKV, Trump DL: Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent infusion, Cancer Res 1990; 50:2667-2672.
12. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M: Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients, Cancer Res 1988:48:1676-1679.
13. Harris BE, Song R, Soong S, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion, Cancer Res 1990:50:197-201.
14. Etienne MC, Milano G, Lagrange JL, Bajard F, Francois E, Thyss A, Schneider M, Renee N, Fety R: Marked fluctuations in drug plasma concentrations caused by use of portable pumps for fluorouracil continuous infusion, J Natl Cancer Inst 1993;85:1005-1006.
15. Czejka MJ, Jäger W, Schüller J, Fogl U, Weiss C, Schernthaner G: Clinical pharmacokinetics of 5-Fluorouracil, Drug Res 1993;43:387-390.
16. Yoshida T, Araki E, Iigo M, Fujii T, Yoshino M, Shimada Y, Saito D, Tajiri H, Yamaguchi H, Yoshida S, Yoshino M, Ohkura H, Yoshimori M, Okazaki N: Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer, Cancer Chemothcr Pharmacol 1990:26:352-354.
17. Grem JL, McAtee N, Balis F, Murphy R, Venzon D, Kramer B, Goldspiel B, Begley M, Allegra CJ: A phase II study of continuous infusion of 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma, Cancer 1993;72:663-668.
18. Spicer DV, Ardalan B, Daniels JR, Silberman H, Johnson K: Réévaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics, Cancer Res 1988:48:459-461.
19. Peters GJ, Codaeel-Pisanelli G, van der Wilt CL, van Laar JAM, Smid K, Noordhuis P, Pinedo HM: Comparison of continuous infusions and bolus injections of 5-fluorouracil with or without leucovorin: Implications for inhibition of thymidilate synthase; in Rustum YM (ed): Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation, Plenum Press New York, 1993. pp 9-21.